mosunetuzumab
Selected indexed studies
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. (Lancet Oncol, 2022) [PMID:35803286]
- Mosunetuzumab. (, 2006) [PMID:36701508]
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. (J Clin Oncol, 2025) [PMID:41037766]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. (2025) pubmed
- Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. (2024) pubmed
- Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. (2025) pubmed
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. (2022) pubmed
- Mosunetuzumab. (2006) pubmed
- Mosunetuzumab: First Approval. (2022) pubmed
- Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. (2025) pubmed
- Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. (2023) pubmed
- Mosunetuzumab for the treatment of follicular lymphoma. (2024) pubmed
- Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma. (2023) pubmed